Tag: NIH
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Featured Article
Reducing downtime through real-time shop floor insights with Minitab’s Prolink
Unplanned downtime remains one of the most costly – and often misunderstood – challenges on the manufacturing floor.
